師資

張健
教授
百千萬人才工程國家級人選
0755-88018036
zhangjian@sustech.edu.cn
個人主頁

主要學術成績簡介

張健,南方优乐园彩票开户大学醫學院教授,博士生导师, 百千萬人才工程国家级人选,国务院特贴专家,深圳市引进国家级领军人才,美国匹茨堡大学醫學院兼职教授,中国抗癌协会肿瘤转移专业委员会常委兼青委会主任委员,中国医药生物技术学会转化医学分会常委,中国细胞生物学会医学细胞生物学分会常委,深圳市生物医药促进会副会长,曾创建長壽與老年相關疾病研究教育部重點實驗室任首任主任和學術委員會副主任,目前擔任廣東省細胞微環境與疾病研究重點實驗室學術委員會成員和深圳市細胞微環境重點實驗室學術委員會成員。2015-2017年擔任《Medical Oncology》副主編。SCI 發表文章總數100余篇。 博士毕业于美国密西根大学醫學院,2004 年起任美國國防部(DOD)醫學課題評審委員,從2009 年起任我國教育部長江學者和自然科學基金終審評審專家。2012 年被選爲全國優秀优乐园彩票开户工作者 2013 年入選国家百千萬人才工程國家有突出貢獻中青年專家2016年獲批深圳市引進國家級傑出人才。主要研究方向:腫瘤耐藥和轉移。

 

教育經曆

1981-1986: 学士,天津医科大学临床医学系

1997-1998: 硕士,Old Dominion University & East Virginia Medical School 免疫学专业

1998-2001: 博士,?University of Michigan 病理学专业

?

主要工作經曆

1986.8-1995.1 ?天津市第三医院/天津市老年医学研究所,内科住院医师、主治医师

1995.1-1996.8?? 美国威斯康星-麦迪逊大学老年医学研究所 世界卫生组织奖学金访问学者

1996.8-1998.8 ?东弗吉尼亚醫學院老年医学研究中心Visiting Research Scientist

1998.8-2004.6?? ?美国密歇根大学醫學院博士在学/研究员

2004.7-2010.12?? 美国匹兹堡大学和密歇根大学醫學院助理教授 (Tenure track)

2011.1-2016. 7?? 长寿与老年相关疾病省部共建教育部重点实验室/广西医科大学转化醫學院就中心主任/教授

2016.3-???????????? 美国匹兹堡大学醫學院兼职教授

2016.7-???????????? 南方优乐园彩票开户大学醫學院教授

 

研究方向

腫瘤轉化醫學研究

腫瘤轉移與耐藥

衰老與腫瘤

 

榮譽

2019-深圳市生物醫藥促進會副會長

2018-中國腫瘤防治聯盟深圳市聯盟副主席

2014-獲得國務院政府特殊津貼專家

2013-入选国家百千萬人才工程國家級人選并获“有突出贡献的中青年专家”榮譽称号

2013-美国基础泌尿研究学会(SBUR)颁发的International lecturer证书

2012-全國優秀优乐园彩票开户工作者

2011-廣西自治區八桂學者、廣西自治區政府參事

2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR

2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR

2003-Scholar-in-Training Award, AACR

2003- Plenary Poster Award of 25th Annual Meeting of American Society for Bone and Mineral Research

2002-Alice L. Jee Memorial Young Investigator Award

2000-Plenary Poster Award of 22nd Annual Meeting of American Society for Bone and Mineral Research

1994- Fellowship Award, World Health Organization (WHO)

 

代表著作

  1. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.
  2. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling. 3:493-504, 2001.
  3. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256-1263, 2002.
  4. Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003
  5. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. Prostate. 59:360-9, 2004
  6. Zhang J, Dai J, Lu Y, Yao Z, O’Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004
  7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311-8, 2006
  8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646-53, 2007
  9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*.?? CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007
  10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007
  11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.?? Int J of Cancer. 121:724-733, 2007
  12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Mol Cancer Therapeutics, 7(10):3203-11, 2008
  13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6(4): 546-54, 2008
  14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2):161-9, 2009
  15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia, 11(3):228-236, 2009
  16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010
  17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010
  18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011
  19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.
  20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*,Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One. 9(6):e100394, 2014
  21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5; 473-86
  22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J*. Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294
  23. Yu?Zhu,?Chunlin?Zou,?Zhe?Zhang,?Chaonan?Qian,?Xin?Yang,?Junlin?Shi,?Yudui?Xia,??Zhang J*,?Yi?Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. Tumor?Biology, 2015, 36(11):8811-8.
  24. Sha?He,?Yi?Lu,?Xia?Liu,?Xin?Huang,?Evan?Keller, Chao-Nan?Qian*,??Zhang J*; Wnt3a:?function?and?implication?in?cancer. Chinese?Journal?of?Cancer, 2015, 34(3):50.
  25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J*, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway. Oncotarget, 7(10):11487-99, 2016.
  26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49:838-846.
  27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J*, Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports, 2016, 36:559-566.
  28. Yang Liu, Yi Chai, Zhang J*, and Junwei Tang*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.
  29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, Oct 18;7(42):68140-68150.
  30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017; 36(1):17.
  31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2017; 7: 41656.
  32. Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang*. Down-regulation of?E-cadherin enhances prostate cancer chemoresistance via?Notch signaling. Chinese Journal of Cancer, 2017; 36:35
  33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017
  34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang, Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017; 36:29
? 2018 All Rights Reserved. 粵ICP備14051456號